Although the exact mechanism responsible for improved susceptibility to STI-571 by NHERF1 needs further investigation, our present study indicates an inhibitory effect of NHERF1 on PDGF-medicated breast cancer progression and suggests that the status of NHERF1 expression in breast tumor influences how patients respond to STI-571. This evidence concerns the gene NHERF1 and breast cancer.